Recipharm commits SEK5m to bioanalysis lab citing lack of Nordic capacity

Recipharm commits SEK5m to bioanalysis lab citing lack of Nordic capacity
The contract manufacturing firm said it will build the new lab at a site in Uppsala, Sweden, explaining that the facility will have capacity to process 10,000 plasma samples a week.Fredrik Lehmann, General Manager at Recipharm Development in Uppsala told us the laboratory will offer a range of bioanalysis services, with a focus on the assessment of clinical and toxicology samples.He added that the site will conduct bioanalysis work for a variety of drug types “mostly small molecule, but not exclusively, some large molecules will also be handled.”Nordic capacitySweden is a base of operations for some of the largest drug manufacturers in the world. For example, Pfizer and AstraZeneca both have production operations in the country.But there is a lack of good laboratory practice standard bioanalysis labs in Sweden and across the Nordic region as a whole according to Lehmann, who cited the shortage alongside customer demand as a driver for the investment.“Some major pharma might, or might not, have capacity in-house, but looking at all the GLP certificates that are issued in Sweden, there are not t…

Be the first to comment on "Recipharm commits SEK5m to bioanalysis lab citing lack of Nordic capacity"

Leave a comment

Your email address will not be published.

*